Therefore, relevant nuclear staining in a sub-diagnostic manner (focal and weak) but not cytoplasmic staining may be meaningful in mesenchymal tumors when further validated by RNA-based targeted NGS in all advanced and metastatic ALK negative-IMTs; this can identify patients who will benefit from TRK inhibitor therapy. This evidence concerns the gene TPM3 and mesenchymal cell neoplasm.